异质性万古霉素耐药金黄色葡萄球菌感染研究进展(4)
 |
| 第1页 |
参见附件(2134KB，3页)。
[19] Tillotson, G. S., D. C. Draghi, D. F. Sahm, K. M. Tomfohrde, T. Del Fabro, and I. A. Critchley. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratorybased surveillance study. J. Antimicrob. Chemother,2008,62:109-115.
[20] Bishop, E., S. Melvani, B. P. Howden, P. G. Charles, and M. L. Grayson. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob. Agents Chemother,2006,50:1599-1602.
[21] Muthaiyan A,Silverman JA,Ayaswal RK,et al. Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to memvrane depolarization.Antimicrob Agents Chemother,2008,52(3):980-990.
[22] Hirschwerk, D., C. C. Ginocchio, M. Bythrow, and S. Condon. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect. Control Hosp. Epidemiol,2006,27:315-317.
[23] Samra, Z., O. Ofir, and H. Shmuely.In vitro susceptibility of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium to daptomycin and other antibiotics. Eur. J. Clin. Microbiol. Infect. Dis,2007,26:363-365.
[24] Jevitt, L. A., A. J. Smith, P. P. Williams, P. M. Raney, J. E. McGowan, Jr., and F. C. Tenover. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium ......
您现在查看是摘要介绍页，详见PDF附件(2134KB，3页)。